X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
RTA 744 (berubicin hydrochloride) is an anthracycline, which is designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells. It is being evaluated in phase 2 clinical trials for the treatment of glioblastoma multiforme.
Lead Product(s): Berubicin
Therapeutic Area: Oncology Product Name: Berubicin
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc.
Lead Product(s): Berubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
The Company decided to implement a dual-track drug product manufacturing strategy in order to mitigate both COVID-19 related risks, as well as to diversify its supply chain and reduce the risk that inefficiencies could impact the Company's clinical timeline.
Lead Product(s): Berubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
CNS Pharmaceuticals has engaged Berry Consultants, a leading clinical statistical consulting group, to advise the Company ahead of its Phase 2 trial regarding its lead drug candidate Berubicin.
Lead Product(s): Berubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
In the Phase 1 trial of Berubicin to treat glioblastoma, under a prior developer, 44% of the patients demonstrated a significant improvement in progression free survival, and one patient experienced a complete response.
Lead Product(s): Berubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
Designation based on the results of prior Phase 1 trial of Berubicin in which 44% of the patients demonstrated a significant improvement in progression free survival.
Lead Product(s): Berubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
In the Phase 1 trial, 44% of patients experienced a statistically significant improvement in progression-free survival.
Lead Product(s): Berubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
Details:
The Company, in collaboration with CNS, is planning to conduct the upcoming Phase I clinical trial at Children's Memorial Health Institute
Lead Product(s): Berubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2020
Details:
For the large scale production of Berubicin, its lead drug candidate for the treatment of glioma brain tumors.
Lead Product(s): Berubicin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: NCK AS
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
